|
Adrenal Gland Hyperfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In this regard, impaired adrenocortical function is likely induced by atrophy of the residual adrenal tissue as a result of chronic suppression by the low ACTH levels of the hypercortisolism state.
|
30915117 |
2019 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Additional biochemistry confirmed adrenocorticotropic hormone-independent hypercortisolism.
|
31492730 |
2019 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The neurosurgical resection of her 2 mm adrenocorticotropic hormone (ACTH) secreting pituitary microadenoma resulted in a successful resolution of the patient's hypercortisolism and a significant recovery of her neurocognitive function.
|
31253144 |
2019 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
All patients had suppressed 8 am adrenocorticotropic hormone (ACTH) (<10 pg/mL) despite evidence of hypercortisolism.
|
30875328 |
2019 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A mono-centric and longitudinal study was conducted on 19 consecutive patients who underwent SBA for ACTH-dependent hypercortisolism between December 2003 and December 2017.
|
31583577 |
2019 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cushing's disease (CD) is a rare condition caused by adrenocorticotropic hormone (ACTH)-producing adenomas of the pituitary, which lead to hypercortisolism that is associated with high morbidity and mortality.
|
31717455 |
2019 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A retrospective analysis of ten consecutive patients with ACTH-independent hypercortisolism who underwent AVS at our institution between 2009 and 2017.
|
31440949 |
2019 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Adrenal functional autonomy has been described in a subset of patients with CD, leading to the hypothesis of transition from ACTH-dependent to ACTH-independent hypercortisolism.
|
31276155 |
2019 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Endocrine evaluation confirmed active acromegaly and revealed adrenocorticotropin hormone-dependent hypercortisolemia.
|
31505284 |
2019 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
It has been thought that inhibition of a glucocorticoid positive-feedback loop is associated with remission of hypercortisolism in ACTH-dependent cyclic Cushing syndrome.
|
30561712 |
2019 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The Role of Cortisol/ACTH Ratio for Screening of Subclinical Hypercortisolism in Patients with Adrenal Incidentalomas.
|
28931176 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
High-dose Dexamethasone suppression testing suggested ACTH-dependent ectopic hypercortisolism.
|
29755405 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Elevated serum cortisol level of 95.7 µg/dL (8.7-22.4 µg/dL) and markedly elevated 24-hour urinary cortisol level of 6962.3 µg/24 hours (4.0-50.0 µg/24 hours) with concurrent adrenocorticotropic hormone (ACTH) level of 171 pg/mL (6-58 pg/mL) were suggestive of an ACTH-dependent source of hypercortisolism.
|
29535093 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A glucocorticoid-driven positive-feedback regulation in this ectopic ACTH-secreting pheochromocytoma created a vicious cycle with rapid exacerbation of both hypercortisolemia and hypercatecholaminemia with extremely elevated plasma ACTH level.
|
29760304 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The aim of the study is to detect these receptors in two patients with ACTH-independent hypercortisolism by means of the application of a screening protocol.
|
29936051 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
There were significantly fewer patients with hypercortisolism in the higher ACTH group; midnight serum cortisol levels were associated with hypercortisolism only in the lower ACTH group.
|
30414423 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The clinical features of hypercortisolism result from elevated levels of adrenocorticotropic hormone produced by a tumor.
|
30036246 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The participation of aberrant receptors and intra-adrenal ACTH in hyperplastic tissue are considered mechanisms that regulate hypercortisolism in PMAH.
|
28676429 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Biochemical testing confirmed hypercortisolism with extremely elevated levels of plasma adrenocorticotropin, urinary cortisol and multiple steroids of a plasma panel that were all normal at previous testing.
|
28937294 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
OBJECTIVE Cushing disease is caused by a pituitary micro- or macroadenoma that hypersecretes adrenocorticotropic hormone (ACTH), resulting in hypercortisolemia.
|
29027854 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Cushing's disease results from corticotroph adenomas of the pituitary that hypersecrete adrenocorticotropin (ACTH), leading to excess glucocorticoid and hypercortisolism.
|
30093687 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Endocrinological investigation confirmed severe hypercortisolism along with elevated plasma adrenocorticotropin hormone (ACTH).
|
29921267 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Effect of hypercortisolism on bone mineral density and bone metabolism: A potential protective effect of adrenocorticotropic hormone in patients with Cushing's disease.
|
28851260 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
For our study, we compared patients with ACTH-independent hypercortisolaemia (n = 25) with those with Cushing's syndrome (n = 19).
|
29952409 |
2018 |
|
Adrenal Gland Hyperfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Most of these patients shared the following features of CS: skin thinning, severe hypercortisolemia (24-hour urinary free cortisol ≥10 times the upper limit of normal), ectopic secretion of ACTH, and severe hypokalemia.
|
29846662 |
2018 |